---
figid: PMC7464161__cancers-12-02143-g008
figtitle: Possible mechanism of action of metformin and everolimus in QGP-1 and H727
  cells
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
- Danio rerio
pmcid: PMC7464161
filename: cancers-12-02143-g008.jpg
figlink: pmc/articles/PMC7464161/figure/cancers-12-02143-f008/
number: F8
caption: Schematic representation of the possible mechanism of action of metformin
  and everolimus in QGP-1 and H727 cells. Metformin acts via 5′-AMP-activated protein
  kinase (AMPK) dependent or independent pathways, leading to mTORC1 complex inhibition.
  Everolimus inhibits mTOR phosphorylation, but its long-term use is limited by the
  development of resistance, probably due to the activation of Akt signaling. The
  combination of metformin and everolimus induces a more potent blockade of mTOR and
  potentially counteracts the resistance mechanisms triggered by everolimus. (A) In
  QGP-1 cells metformin did not affect Akt phosphorylation, probably acting through
  the AIP pathway to decrease mTOR phosphorylation. (B) In H727 cells, metformin decreases
  Akt phosphorylation to suppress mTOR phosphorylation.
papertitle: 'Metformin and Everolimus: A Promising Combination for Neuroendocrine
  Tumors Treatment.'
reftext: Eleonora Vitali, et al. Cancers (Basel). 2020 Aug;12(8):2143.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9420091
figid_alias: PMC7464161__F8
figtype: Figure
redirect_from: /figures/PMC7464161__F8
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7464161__cancers-12-02143-g008.html
  '@type': Dataset
  description: Schematic representation of the possible mechanism of action of metformin
    and everolimus in QGP-1 and H727 cells. Metformin acts via 5′-AMP-activated protein
    kinase (AMPK) dependent or independent pathways, leading to mTORC1 complex inhibition.
    Everolimus inhibits mTOR phosphorylation, but its long-term use is limited by
    the development of resistance, probably due to the activation of Akt signaling.
    The combination of metformin and everolimus induces a more potent blockade of
    mTOR and potentially counteracts the resistance mechanisms triggered by everolimus.
    (A) In QGP-1 cells metformin did not affect Akt phosphorylation, probably acting
    through the AIP pathway to decrease mTOR phosphorylation. (B) In H727 cells, metformin
    decreases Akt phosphorylation to suppress mTOR phosphorylation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IGF1
  - IGF1R
  - IRS1
  - STK11
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - AKT1
  - AKT2
  - AKT3
  - TSC1
  - CCL26
  - TSC2
  - AIP
  - AURKAIP1
  - MTOR
  - Lkb1
  - SNF4Agamma
  - AMPKalpha
  - Akt
  - Tsc1
  - gig
  - Mtor
  - Tor
  - igf1
  - igf1rb
  - irs1
  - tsc1b
  - tsc2
  - aip
  - mtor
  - Metformin
  - Everolimus
---
